Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Status:
Completed
Trial end date:
2008-03-17
Target enrollment:
Participant gender:
Summary
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated
dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients
with relapsed/progressive osteosarcoma metastatic to the lung.